About Us

Discover our vision and connect with us to start a partnership and project.

Our mission

Samplix ApS supports the life sciences and medical research communities with proprietary microfluidics-based solutions and services designed to deliver the highest-resolution insights into cells and genomes. Samplix technology is designed for encapsulating biological material, including single cells, organelles and  molecules, for a range of downstream analyses, such as assessments of single-cell enzyme activity, characterisation of edits in engineered genes, long- and short-read sequencing, and low-bias whole genome amplification.

As a leading developer of microfluidics solutions and services, Samplix stands ready to help academic, corporate and government researchers reach their goals in areas as diverse as human genomics, gene and cell therapy, plant genomics, and synthetic biology.

Our history

How do you get error- and bias-free identification of genomic variants? This was the question that Dr. Marie Just Mikkelsen and Dr. Thomas Kvist wanted to answer in 2012, when they were working on rare genomic variants. At the time, no existing technology could address that important question. Motivated by the challenge, the two scientists set out to develop a method that reveals any genomic variation.

PCR and unintended interactions between DNA molecules during sample handling are often the root of bias and errors in genomic analyses. Marie and Thomas built a team focused on creating a PCR amplification-free workflow with single molecules encapsulated in droplets.

In 2019, after 6 years of product development and thorough testing, the fully developed microfluidics system for droplet-based, PCR-free enrichment of genomic regions was launched under the name Xdrop®.

Since then, Xdrop technology has proven itself in a broad range of applications with human, other animal, plant, and microbial genomes. It also supports the investigation of cell reactions, including enzyme activity and protein synthesis.

With the success of the microfluidics system, Samplix has grown considerably, and now has a Services team that supports customers worldwide with their genomics and molecular biology research.

Our management

 

Lars Kongsbak

CEO

Lars Kongsbak provides expertise in building startups, including strategy drafting and establish competent leadership. He has listed two life science companies and is or has been engaged with BlueBee, ViroGates, Exiqon, Novozymes and Novo Nordisk.

Marie Just Mikkelsen

CTO and co-founder

Marie Just Mikkelsen provides expertise in product development, which for Samplix includes instruments, microfluidics technology, molecular biology reagents, and bioinformatics. She has been engaged with Biogasol and Estibio.

Søren Echwald Morgenthaler

VP Intellectual Property Rights

Søren Echwald Morgenthaler provides expertise in patent strategy, freedom to operate analysis and business strategy. He has listed one life sciences company and is or has been engaged with Anapa Biotech, Exiqon and Novo Nordisk.

Peter Mouritzen

VP Application & Market Development

Peter Mouritzen provides expertise in documenting the many applications of the Xdrop technology and builds relationships with key opinion leaders across the globe. He has listed one life science company and has been engaged with QIAGEN and Exiqon.

Our partnerships

Supporting groundbreaking research is integral to our mission. Samplix has established collaborations with leading researchers in genomics and molecular biology. Here are some recent examples.

Bioneer

Samplix and Bioneer collaborate to tackle challenges in genomics.

Bioneer provides customized gene-editing services, including advanced quality control of gene-edited cell models. Through their partnership with Samplix, they will offer their customers access to Xdrop technology.

 Learn more: Bioneer and CRISPR editing verification.

200527 Samplix Bioneer v4

Uppsala University and SciLifeLab

“We have had a long collaboration with the Samplix team. They have listened to our feedback, and we are glad to see how far this technology has come since the early days when we received the world’s first Xdrop in our lab”

- Dr. Adam Ameur, Uppsala University & SciLifeLab

Dr. Adam Ameur from Uppsala University and Science for Life Laboratory (SciLifeLab) has used Xdrop for several projects, including target enrichment and single-molecule sequencing of the TP53 gene for phasing variants in DNA from leukemia patients. With the support of Xdrop, Dr. Ameur and his team successfully phased point mutations present in the leukemia cancer samples.

Photo of Dr. Adam Ameur of Uppsala University and SciLifeLab

Photo credit: Uppsala University

HORIZON 2020

Samplix was awarded a grant from the European Commission’s prestigious Horizon 2020 SME program. From May 1, 2019 to May 1, 2021, this funding helped accelerate the development of Xdrop technology by optimizing the process and products based on user feedback. The grant allowed Samplix to expand our activities and move towards the aim of the grant: Improving DNA analysis for correct healthcare (IMPACT).

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 848497

euflag

What's new for Samplix?

See the latest news about product releases, webinars and events, partnerships and more.


Samplix is going to The Festival of Genomics and Biodata in London

The Festival of Genomics and Biodata (January 26–28, 2022) is the UK's largest genomics event. Over 7,000 attendees from the global genomics community are expected. Samplix is an exhibitor and a talk sponsor — watch this space for more news about our plans for this prestigious event.

Samplix will be at PAG XXIX in San Diego

The International Plant and Animal Genome XXIX in San Diego will host over 3,000 leading genetic scientists and researchers in plant and animal research. Samplix experts are joining the event. Watch this space for more details.

Xdrop used in study of underlying cause of genetic disorders

How can we better study genotype–phenotype correlation in genetic disorders and potentially enable more efficient diagnosis? Published in Frontiers in Genetics, this important paper details how to overcome the limitations of traditional methods for the analysis of repeat extensions using microfluidics droplet-based DNA preparation using Xdrop and sequencing using Oxford Nanopore Technologies and Illumina. The study was done by an inter-institutional team including researchers from the University of Verona, the University of Rome Tor Vergata​, the University of Nevada at Reno, GENARTIS and IRCCS.

Samplix attended the MiFFI conference in Copenhagen

The second international conference on Microbial Food and Feed Ingredients (MiFFI) was in Copenhagen from November 16 to 18. Samplix experts were at Booth C2 to answer questions and demonstrate how microfluidics technology can boost the resolution and throughput of single-cell investigations and synthetic biology workflows.